Meet the Coalition

The Canadian Association of Nuclear Medicine strives for excellence in the practice of diagnostic and therapeutic nuclear medicine by promoting the continued professional competence of nuclear medicine specialists, establishing guidelines of clinical practice, and encouraging biomedical research. CANM works with all professionals in nuclear medicine to ensure that Canadians have access to the highest quality nuclear medicine services.

Canadian Cancer Survivor Network is a a national network of patients, families, survivors, friends, community partners and sponsors. CCSN’s mission is to work together by taking action to promote the very best standard of care, support, follow-up and quality of life for patients and survivors.

CCSN aims to educate the public and policy makers about cancer and encourage research on ways to alleviate barriers to optimal cancer care in Canada.

CNETS was formed in 2007 to assist the Canadian community, primarily patients, with this type of disease. CNETS provides workshops and seminars, establishes support groups and services, educated the public and healthcare professionals on carcinoid and related neuroendocrine tumours.

The Canadian Nuclear Isotope Council (CNIC) is an independent, not-for-profit advocacy organization that supports over 90 members from across science, academia, healthcare, and the nuclear industry.

The CNIC serves as a voice in safeguarding the continued availability of isotopes, ensuring our public policies are risk-informed and science-based, and support the highest levels of public health and safety. Leveraging existing infrastructure and expertise will have a significant positive impact on human health across the globe, keeping hospitals clean and safe while expanding Canada’s leadership role in the global medical community by supporting new and innovative treatments.

Curium is a world-class nuclear medicine solutions provider. With manufacturing facilities across Europe and the United States, Curium supports over 14 million patients around the world with SPECT, PET and therapeutic radiopharmaceuticals to provide potentially life-saving diagnostic solutions. The Curium brand name is inspired by the work of radiation researchers Marie and Pierre Curie and emphasizes our focus on nuclear medicine.

Since 1976, Hermes Medical Solutions has continuously innovated to enable faster and more personalized diagnosis and therapies in molecular imaging. The company was first to develop SPECT reconstruction software and fusion software for combined viewing of images from different scanners. With the HERMIA software, physicians can perform fast and accurate reporting for ALL scenarios in SPECT-CT, PET-CT, PET-MR, including theranostics, onsite or remotely. The result is improved quality in patient management and decision support.

IBA is the world leader for the supply of PET & SPECT cyclotrons for radiopharmaceuticals production. Headquartered in Belgium, IBA installed and supports over 300 cyclotrons across the world. Based on 35 years of experience, IBA RadioPharma Solutions helps nuclear medicine department to design, build and operate PET center for the production of radiopharmaceuticals used for the detection and treatment of cancer and other critical diseases.

Dr. Christopher O’ Brien, Director of Nuclear Medicine for the Brant Community Healthcare System

Dr. Kate Savelberg, Professor of Nuclear Medicine at The Michener Institute of Education at University Health Network

INITIO is Western Canada’s only private PET/CT scan facility. With over 20 years experience, we offer Rapid PET/CT and CT scans and nuclear medicine treatments with no wait list. INITIO has diagnostic scanning for cancer, cognitive impairment, and cardiac sarcoidosis, and now, offers prostate cancer therapy. With this latest addition, INITIO Medical Group reaffirms its commitment to providing the most advanced and effective treatments to its patients. We are proud to be able to offer Lu-177 PSMA therapy and look forward to the positive impact it will have on the lives of those affected by prostate cancer.

Isologic Innovative Radiopharmaceuticals (ISOLOGIC) is a nationwide radiopharmaceutical company, dedicated to nuclear medicine and the science of radiopharmaceutical production. Their commitment to these fields extends to the communities we serve. They have over 200 team members focused on serving our customers and their patients. They utilize their significant experience, expertise and networks in nuclear pharmacy to provide their customers and patients with reliable; safe and high quality radiopharmaceutical products and services.

Life Molecular Imaging (LMI) was formed in 2012 and offers an integrated business including research and development laboratories, a network of cyclotrons, radiopharmacies and imaging facilities. By developing novel PET tracers for molecular imaging, LMI is focusing on a key field of modern medicine. The organization strives to be a leader in the molecular imaging field by developing innovative products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life.

The Oncidium Foundation is a non-profit and public benefit organization dedicated to raising awareness about radiotheranostics for cancer care and providing support to accelerate global access. The foundation leads the way in this patient-focused science, connecting people to advance the availability of this innovating and life-saving technology.

The Oncidium Foundation is a worldwide hub connecting patients, practitioners and experts in the nuclear medicine field.

OPACC was founded in 1995 with a mission to support families of children diagnosed with cancer in Ontario, Canada.

OPACC offers various free support programs and services, including peer-to-peer in-hospital and virtual support through a Parent Liaison program, financial support including helping to pay for hospital parking and distributing grocery gift cards and hospital meal vouchers, community-based parent support groups, and much more.

Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic ('theranostic') radiopharmaceuticals. Telix is developing a portfolio of radiopharmaceutical products that aims to address significant unmet medical need in oncology and rare diseases.